Oravax brings together a virus-like particle VLP vaccine technology, developed by Premas Biotech with Orameds proprietary protein oral delivery POD technology in the development of oral vaccines.Premas virus-like particle VLP vaccine technology, based on its D-CryptTM platform, targets three SARS CoV-2 virus surface proteins, including proteins less susceptible to mutation, thus making the vaccine potentially more effective against current and future variants of the COVID19 virus.
ICT to host training workshop on COVID-19 from Oct 4-8, 2021 biospectrumindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospectrumindia.com Daily Mail and Mail on Sunday newspapers.
Orameds jab-free oral Covid-19 vaccine is one of many in the form of pills, powders, or sprays that may hit the market in the next few years, which could dramatically expand vaccine rollout and uptake. An Israeli team is preparing to start trials of what could be the first Covid-19
Premas Biotech secures licensing deal with Oravax Medical for vaccine tech biospectrumindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospectrumindia.com Daily Mail and Mail on Sunday newspapers.
Premas Biotech secures licensing deal for commercializing its vaccine technology in India aninews.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from aninews.in Daily Mail and Mail on Sunday newspapers.